No Data
No Data
Analysts' Opinions Are Mixed on These Healthcare Stocks: KalVista Pharmaceuticals (KALV), Roche Holding AG (OtherRHHVF) and Pfizer (PFE)
HC Wainwright & Co. Reiterates Buy on KalVista Pharma, Maintains $20 Price Target
HC Wainwright & Co. analyst Andrew Fein reiterates KalVista Pharma (NASDAQ:KALV) with a Buy and maintains $20 price target.
H.C. Wainwright Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright analyst Andrew Fein maintains $KalVista Pharmaceuticals(KALV.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate
Buy Rating on KalVista Pharmaceuticals: Sebetralstat Poised to Transform HAE Treatment Landscape
Companies Like KalVista Pharmaceuticals (NASDAQ:KALV) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. For example, although software-as-a-service business Salesforce.com lost money for years while it grew
Needham Adjusts Price Target on KalVista Pharmaceuticals to $32 From $35, Maintains Buy Rating
KalVista Pharmaceuticals (KALV) has an average buy rating and price target range of $20 to $39, according to analysts polled by Capital IQ.Price: 12.82, Change: +0.32, Percent Change: +2.56